Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06117709 · ClinicalTrials.gov registry record · NA
Integrated Smartphone Technology to Alleviate Malignant Pain (I-STAMP) Testing
A NA study, sponsored by Dana-Farber Cancer Institute.
- Not yet
- Registry status
- NA
- Development phase
- 73
- Enrollment target
NCT06117709: Clinical Trial NA study, sponsored by Dana-Farber Cancer Institute.
NCT06117709 is a NA study that has not yet begun recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 73 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06117709, a NA study, has not yet begun recruiting, sponsored by Dana-Farber Cancer Institute.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 73 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate if the smartphone app, I-STAMP (Integrated Smartphone Technology to Alleviate Malignant Pain), helps participants with cancer pain manage symptoms and keep track of medications.
Primary Outcome
Patients will complete a validated 10-item system usability scale (SUS) with total scores ranging from 0-100, where a score of 100 being the best possible usability score.
Interventions
- BEHAVIORAL I-STAMP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2026-05 |
| Est. Completion | 2026-08-30 |
| Phase | NA |
What is known before NCT06117709 opens enrollment
NCT06117709 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 73 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which I-STAMP is the first listed.
NCT06117709 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06117709 about?
NCT06117709 is a clinical study titled "Integrated Smartphone Technology to Alleviate Malignant Pain (I-STAMP) Testing". The purpose of the study is to evaluate if the smartphone app, I-STAMP (Integrated Smartphone Technology to Alleviate Malignant Pain), helps participants with cancer pain manage symptoms and keep track of medications.
What is the current status of trial NCT06117709?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 73 participants. The study started on 2026-05. Estimated completion is 2026-08-30.
What interventions are being tested in trial NCT06117709?
The interventions under investigation include: I-STAMP (BEHAVIORAL).
Who is sponsoring clinical trial NCT06117709?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06117709's enrollment target sits among peer trials
73 1089th of 2000 higher than 912 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03661307 · 73 participants · Phase 1
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- NCT05386108 · 73 participants · Phase 1
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- NCT05961592 · 73 participants · Phase 1
R-2487 in Patients With Rheumatoid Arthritis
- NCT06150664 · 73 participants · Phase 1
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia